Tagrisso with chemo considerably improved survival and progression-free outcomes versus Tagrisso alone in newly identified superior EGFR-mutated lung most cancers: © inventory.adobe.com.
Including chemotherapy to Tagrisso (osimertinib) improved total survival for sufferers with newly identified, superior EGFR-mutated non-small cell lung most cancers in contrast with Tagrisso alone, in accordance with a information launch from AstraZeneca.
“When treating lung most cancers, the goal is to each extend survival and enhance the affected person expertise, particularly in 1st-line the place therapy period will be lengthy and plenty of sufferers stay lively,” Dr. Pasi A. Jänne stated within the information launch. “These constructive outcomes assist [Tagrisso], both as monotherapy or together with chemotherapy, as commonplace of look after sufferers with 1st-line superior EGFR-mutated lung most cancers and reinforce the significant good thing about the mix within the present medical setting. The noticed survival profit is especially spectacular provided that FLAURA2 didn’t impose any restrictions on the selection of subsequent therapy after illness development.”
Jänne is the senior vice chairman for Translational Medication and thoracic medical oncologist at Dana-Farber Most cancers Institute and principal investigator for the FLAURA2 trial
The ultimate total survival (OS) evaluation demonstrated a constant survival profit with Tagrisso plus chemotherapy, confirming the pattern seen within the interim outcomes and constructing on beforehand reported major endpoint information, which confirmed the longest median progression-free survival (PFS) reported on this setting.
On the time of the interim evaluation, performed with 41% information maturity, Tagrisso plus chemotherapy confirmed a good OS pattern versus Tagrisso alone, with constant profit throughout prespecified subgroups, together with intercourse, race, EGFR mutation sort, age, smoking historical past, efficiency standing and presence of mind metastases. Whereas the OS outcomes weren’t statistically vital on the interim evaluation, they had been supported by key post-progression outcomes.
Tagrisso plus chemotherapy confirmed constant profit throughout time to first subsequent therapy, time to development on second-line remedy and time to second subsequent therapy. As the first finish level, PFS was considerably improved with the mix, decreasing the chance of illness development or loss of life by 38%. Median PFS was prolonged by 8.8 months by investigator evaluation and by 9.5 months per blinded impartial central overview. A clinically significant PFS profit was noticed throughout all prespecified subgroups.
With prolonged follow-up, Tagrisso plus chemotherapy confirmed a security profile that remained in step with identified results of every drug. Whereas unwanted effects occurred extra usually with the mix, largely on account of chemotherapy, each teams had low charges of therapy discontinuation from unwanted effects or drug-related toxicities.
“These thrilling total survival outcomes add to the intensive proof supporting Tagrisso because the spine remedy in EGFR-mutated lung most cancers, demonstrating that Tagrisso plus chemotherapy can considerably lengthen survival within the 1st-line superior setting, along with prior trials displaying survival advantages as monotherapy in each early stage and superior illness,” Susan Galbraith, govt vice chairman, Oncology Haematology R&D, AstraZeneca, stated within the information launch. “With its sturdy survival profit and tolerable security profile, this mixture has the potential to assist sufferers reside longer whereas sustaining their high quality of life on therapy.”
Tagrisso is a third-generation EGFR-targeted remedy authorized in over 120 nations for treating EGFR-mutated non-small cell lung most cancers (NSCLC) throughout a number of levels. It’s accessible as 40 mg and 80 mg once-daily tablets and has been utilized by multiple million sufferers worldwide.
The section 3 FLAURA2 trial is a randomized, open-label, multi-center research investigating first-line therapy for sufferers with domestically superior (stage 3B–3C) or metastatic (stage 4) EGFR-mutated non-small cell lung most cancers. Sufferers obtained Tagrisso (80 milligrams [mg] as soon as each day) plus chemotherapy — Alimta (pemetrexed: 500 mg per sq. meter [mg/m2]) with both cisplatin (75 mg/m²) or Paraplatin (carboplatin) — each three weeks for 4 cycles, adopted by upkeep therapy with Tagrisso and Alimta each three weeks.
The trial enrolled 557 sufferers throughout greater than 150 facilities in over 20 nations, together with within the U.S., Europe, South America and Asia. The first endpoint is progression-free survival, with total survival as the important thing secondary endpoint.
References
- “Tagrisso plus chemotherapy demonstrated statistically vital and clinically significant enchancment in total survival in EGFR-mutated superior lung most cancers,” AstraZeneca, March 10, 2025
- “Tagrisso with the addition of chemotherapy confirmed beneficial pattern in total survival in EGFR-mutated superior lung most cancers with additional follow-up from FLAURA2 Section III trial,” AstraZeneca, Might 22, 2024
- “Tagrisso plus chemotherapy prolonged median progression-free survival by almost 9 months in EGFR-mutated superior lung most cancers in FLAURA2 Section III trial,” AstraZeneca, June 2, 2023
For extra information on most cancers updates, analysis and schooling, don’t overlook to subscribe to CURE®’s newsletters right here.
